We are live on ! Find out more
NVRO

NEVRO CORP.

Delisted

NVRO was delisted on the 2nd of April, 2025.

226 hedge funds and large institutions have $6.32B invested in NEVRO CORP. in 2020 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 82 increasing their positions, 70 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more call options, than puts

Call options by funds: $41.8M | Put options by funds: $15.7M

58% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 31

27% more capital invested

Capital invested by funds: $4.98B → $6.32B (+$1.34B)

17% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 70

8% more funds holding

Funds holding: 210226 (+16)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
226
Holders Change
+16
Holders Change %
+7.62%
% of All Funds
4%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
49
Increased
82
Reduced
70
Closed
31
Calls
$41.8M
Puts
$15.7M
Net Calls
+$26.1M
Net Calls Change
+$26M
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
101
Oppenheimer Asset Management
New York
$2.42M -$73.9K -456 -3%
N
102
Natixis
France
$2.39M +$2.23M +13,800 New
Envestnet Asset Management
103
Envestnet Asset Management
Illinois
$2.33M +$97.7K +603 +5%
MIM
104
MetLife Investment Management
New Jersey
$2.33M -$98.5K -608 -4%
Robeco Institutional Asset Management
105
Robeco Institutional Asset Management
Netherlands
$2.21M -$710K -4,386 -26%
PMAM
106
Picton Mahoney Asset Management
Ontario, Canada
$2.18M -$198K -1,221 -9%
First Trust Advisors
107
First Trust Advisors
Illinois
$2.18M -$621K -3,832 -23%
Alyeska Investment Group
108
Alyeska Investment Group
Illinois
$2.04M +$1.9M +11,755 New
Two Sigma Investments
109
Two Sigma Investments
New York
$1.94M -$4.14M -25,576 -70%
Calamos Advisors
110
Calamos Advisors
Illinois
$1.91M -$379K -2,342 -18%
Los Angeles Capital Management
111
Los Angeles Capital Management
California
$1.87M +$8.1K +50 +0.5%
Renaissance Technologies
112
Renaissance Technologies
New York
$1.75M -$15.7M -97,200 -91%
Marshall Wace
113
Marshall Wace
United Kingdom
$1.67M +$1.56M +9,630 New
MLICM
114
Metropolitan Life Insurance Company (MetLife)
New York
$1.67M -$14.7K -91 -0.9%
SCM
115
Soleus Capital Management
Connecticut
$1.66M -$378K -2,337 -20%
UCFA
116
United Capital Financial Advisors
Texas
$1.65M -$750K -4,633 -33%
ASRS
117
Arizona State Retirement System
Arizona
$1.64M -$47.3K -292 -3%
GGHC
118
Gilder Gagnon Howe & Co
New York
$1.62M +$1.52M +9,370 New
Federated Hermes
119
Federated Hermes
Pennsylvania
$1.61M +$1.51M +9,313 New
Bank of Montreal
120
Bank of Montreal
Ontario, Canada
$1.6M +$666K +4,112 +77%
ETC
121
Exchange Traded Concepts
Oklahoma
$1.57M +$802K +4,949 +120%
Voloridge Investment Management
122
Voloridge Investment Management
Florida
$1.57M +$1.47M +9,068 New
Lazard Asset Management
123
Lazard Asset Management
New York
$1.57M +$1.47M +9,059 New
Aviva
124
Aviva
United Kingdom
$1.51M -$1.15M -7,070 -45%
Tudor Investment Corp
125
Tudor Investment Corp
Connecticut
$1.46M +$1.12M +6,920 +464%

NVRO Hedge Fund Activity: Q4 2020 in Review

226 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q4 2020, worth a combined $6.32B — up 27% from $4.98B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new NVRO positions and 31 closed out — a net gain of 18 holders — while 82 added to existing stakes and 70 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $130M. The largest seller was HealthCor Management, cutting an estimated $93.1M.

  • 226 institutional investors held NEVRO CORP. (NVRO) as of Q4 2020, up from 210 in Q3 2020.
  • Funds reported $6.32B of NEVRO CORP. stock for Q4 2020, up 27% quarter-over-quarter.
  • 49 funds opened new NEVRO CORP. positions in Q4 2020 and 31 closed out, a net change of +18 holders.
  • The largest NEVRO CORP. buyer in Q4 2020 was Capital Research Global Investors, an estimated $130M added.
  • The largest NEVRO CORP. seller in Q4 2020 was HealthCor Management, an estimated $93.1M sold.

Based on aggregated 13F filings for Q4 2020.